Back | Best Communication Award | Breakthrough of the Year Award | Best Technology Award |
Mediscience Commentator of the Year Award | Capital Market Transaction of the Year Award |
Most Significant Contribution to the Mediscience Sector Award | The Emerging Star Award |
Chief Executive of the Year Award | Company of the Year Award
Sponsored by MC Services AG
The technology that lies at the heart of this award does not have to be proven, but it will, in the eyes of the Voting Panel, be innovative, well funded, and capable of significant commercial success. The technology concerned could have been developed within the organisation or acquired.
Abivax is focused on developing therapies to effectively treat inflammatory and viral diseases as well as cancer.
The group’s technology is based on cutting-edge science, driven by the goal of developing therapeutics that stimulate the body’s natural immune mechanisms to cure diseases. Abivax’s lead candidate ABX464, is an oral, best-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity based on a novel mechanism of action. The drug effectively puts a brake on inflammation, whereas conventional treatments often lose their effectiveness after a certain duration.
argenx SE is a global immunology company that has developed a pipeline of differentiated antibody therapeutics with its Simple Antibody platform.
Last year argenx and Halozyme Therapeutics announced a global collaboration and license agreement enabling the group to use Halozyme's ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future product candidates. The agreement provides argenx with exclusive access to ENHANZE® for any product targeting the human neonatal Fc receptor FcRn, including argenx's lead asset efgartigimod (ARGX-113) and up to two additional targets. This is significant as it will potentially shorten drug administration time, reduce healthcare practitioner time and offer additional flexibility for patients.
Oxford BioMedica plc
Oxford BioMedica (OXB) is the only FDA-approved lentiviral vector manufacturer worldwide.
Oxford BioMedica’s lentiviral platform is extremely versatile. Its commercial and clinical value has been consistently proven, with partner programmes having increased from nine to nineteen in the period. Further validation of the technology was recently demonstrated with its licence and clinical supply agreement with Juno Therapeutics worth over $200m.
OXB also made significant developments in its bioprocessing capabilities over the past year, including the development of Oxbox, which will further enable the group to support its product pipeline and meet the increasing global demand for lentiviral vectors
Renalytix AI plc
Renalytix AI is an AIM-listed developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease.
The group’s technology platform utilises distinct sources of patient data, including large electronic health records, predictive blood-based biomarkers and genomic information to predict which high risk patients are likely to fall into dialysis.
Renalytix AI hit a number of key milestones on its pathway to FDA approval for KidneyIntelX™ in the period, including key targets for pricing, insurance payor determination and other regulatory markers. The product is already revenue generating and national roll-out is expected later this year in the US.